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Abstract: Hepatitis C virus (HCV) management in the transplant setting is still an open
issue. The therapeutic strategies being addressed include: (a) pre-transplant prophylaxis (to
prevent the infection of the transplanted organ); (b) post-transplant prophylaxis (to reduce
the possibility of developing acute hepatitis); (c) management once the chronic disease has
already set in and stabilized. Combination therapy with peginterferon alfa-2b plus ribavirin
seems to play an important role for patients with established recurrent hepatitis C.
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Epidemiological and clinical issues
Liver transplantation for terminal liver disease due to hepatitis C virus (HCV) infection
is a considerable problem in contemporary society, both because this condition affects
a high number of patients who have undergone liver transplants and because of the
difficulties in managing the post-transplant stage. Over the last 20 years, a dramatic
increase in the number of liver transplants due to hepatitis viruses occurred, in
particular the hepatitis C virus, which is the cause of about 50% of liver transplants
both in the US and in Europe (Curry 2004). This situation is confirmed by Italian
data obtained from the Monotematica AISF (Italian Association for the Study of the
Liver) 2000-Orthotopic Liver Transplantation (OLT)-Study Group (Fagiuoli et al
2002), which demonstrated that the most frequent indication for liver transplantation
is represented by hepatitis B and C (59.4%), and particularly by hepatitis C, which is
responsible for about one third of indications for liver transplantation (Figure 1).
The projections for the future are not encouraging: the impact of hepatitis C on
public health seems bound to grow in the next years. A five-fold increase in the
transplantation requirements due to hepatitis C has been estimated for the decade
1998–2008, on top of an almost three-fold increase in hepatic failures, a more than
two-fold increase in mortality rate due to liver disease, and an increase by 68% and
61% in the cases of hepatic carcinoma and cirrhosis respectively (Davis et al 1998).
One of the main problems to solve after intervention is the prevention of HCV
reinfections of the transplanted organ. Some studies over the last few years have
helped understand the kinetics of the HCV during and immediately after
transplantation. According to a study by Garcia-Retortillo et al (2002) involving 20
consecutive patients who had undergone liver transplantation due to HCV-related
cirrhosis, in most cases a fall in viraemia occurs during the anhepatic stage and in the
stages immediately after reperfusion, probably because of the scarce virion production
and a clearance of the viral load. However, in the following days, viremia tends to
increase quite rapidly and may even exceed the initial values and then stabilize in
chronic hepatitis. Without an effective prophylaxis, the HCV infection recurrence is
almost unavoidable. The reinfection of the transplanted organ usually stems from a
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generally asymptomatic globular hepatitis usually originated
between the first and the fourth month after transplantation.
This form of hepatitis clears up very rarely: more frequently
it evolves into chronic hepatitis. The liver cells necrosis,
with considerable increases in the aminotransferase (ALT)
activity, is not a constant factor in these patients (however,
there seems to be a scarce correlation between ALT serum
values and the severity of the damage of the transplanted
organ) (Bizollon et al 1999). In some cases, within the first
months from transplantation, a sclerosing, cholestatic
hepatitis (with a very serious prognosis) may occur.
Natural history of HCV patients
after liver transplantation
In a period of about 5 years, the chances in favour of
developing cirrhosis of the transplanted organ have been
estimated to vary from 15% to 45%, depending on the data
observed (Gane et al 1996; Feray et al 1999; Prieto et al
1999; Berenguer 2002; Sanchez-Fueyo et al 2002; Neumann
et al 2004a, 2004b) (Figure 2). The factors that seem to
most affect the prognosis, in terms of survival of the patient
and of the transplanted organ, include positivity to HCV
virus, as demonstrated by the USA data obtained from
United Network for Organ Sharing on 11 036 patients who
have undergone 11 791 transplants (Forman et al 2002).
Indeed, liver transplantation in HCV-positive patients has
proved to be correlated to a higher mortality rate (hazard
ratio [HR] 1.23; 95% confidence interval [CI], 1.12–1.35)
and loss of the transplanted organ (HR 1.30; 95% CI, 1.21–
1.39) as compared to HCV-negative transplanted patients.
This difference seems to increase with time. These data have
been confirmed by another study by Berenguer et al (2002)
involving 522 patients who had undergone liver
transplantation due to hepatitis C cirrhosis. After 5 years of
follow up, the percentage of deceased patients in the
HCV-positive group was significantly higher than in the
HCV-negative group (37% vs. 22%; p<0.001). After 7 years
of follow-up, this trend is confirmed: for the HCV-positive
group, the survival rate amounted to 77% after 1 year, 61%
after 5 years, and 55% after 7 years, whereas in the HCV-
negative group it amounted to 87%, 76%, and 70%
respectively (p=0.0001). The main cause of death in HCV-
negative patients is the decompensated cirrhosis of the
transplanted organ (22%). The natural history of cirrhosis
development is different in the pre- and post-transplant
stages (Berenguer 2003), as the disease progression is much
faster after liver transplantation (Table 1).
In this stage the median time to cirrhosis is much shorter
(about one third, or even half) than the time recorded when
no transplant has been performed. The hepatic failure rate
after the development of cirrhosis is also dramatically
different: it amounts to 20%–25% in 10 years before
Table 1 Natural history of hepatitis C before and after
transplantation
Pre-OLT Post-OLT
Fibrosis progression 0.2/year 0.3/year
(units fibrosis/year) (0.09–0.8/year) (0.004–2.19/year)
Median time to cirrhosis 20–30 years 10–12 years
Decompensation rate 20%–25% in 50% in 1 year
afterdevelopment of 10 years
cirrhosis
Survival after 50% in 5 years 41% at 1 year
decompensation
Overall patient survival Not different in Lower in HCV vs
HCV vs nonHCV nonHCV
Abbreviations: HCV, hepatitis C virus, OLT, orthotopic liver transplantation.
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Figure 1 Indications for liver transplantation.
Abbreviations: ETOH, alcohol (ethanol); FHF, fulminant hepatic failure; HBC,
hepatitis B virus; HCV, hepatitis C virus; PBC, primary biliary cirrhosis.
Figure 2 Cumulative probability of developing HCV–graft cirrhosis.Therapeutics and Clinical Risk Management 2006:2(1) 41
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transplantation and 50% in only 1 year after transplantation.
Moreover, the survival rate after the onset of hepatic failure
is much lower after transplantation: 50% in 5 years before
transplantation and 41% in only 1 year after transplantation.
After transplantation, the progression of the disease may
be affected by various factors. HCV reinfection is present
in almost all cases. In 25%–45% of cases a clinically patent
acute hepatitis is recorded, part of which (about 6%) is in a
sclerosing cholestatic form. A very high percentage of
patients (up to almost 100%) develop chronic hepatitis.
Furthermore, it is estimated that in 5–7 years about half of
the patients develop cirrhosis and, later on, hepatic failure
(Figure 3).
Many factors may affect this progression of the disease
and the development of short- and long-term outcomes.
These factors may be associated with the host (human
leucocyte antigen [HLA], race, gender, age, immune genetic
background, immune system) or may be external such as
immunosuppression, alcohol, viral coinfections, the
presence of cytomegalovirus, and antiviral therapy. An
important role in the progression of the disease is also played
by viral factors (ie, viral load, genotype 1 and 4,
quasispecies), factors associated with the donor (ie, age,
sex, steatosis, iron content) and the surgical operation
(warming ischemic time) (Shuhart et al 1997; Charlton et
al 1998; Ghobrial et al 2001; Berenguer et al 2002; Burak
et al 2002; Wali et al 2002; Zekry et al 2003; Machicao et al
2004; Neumann et al 2004a). A faster progression is
generally recorded when other factors are present at the time
of transplantation, such as a high viral load, genotype 1b
(most transplanted patients have this genotype which
responds with more difficulty to the antiviral therapy), the
donor’s age > 50 years and a long ischemic time. The use of
antirejection treatments with cortisone or monoclonal
antibodies, an intense immunosuppressive therapy, and the
onset of a cytomegalovirus infection contribute to
determining a worse prognosis.
Therapeutic options
In summary, the problem of HCV infections after liver
transplantation is extremely complex and has a strong
impact, not only because HCV is the first indication for
liver transplantation (and estimates show a further increase),
but also because a relapse of the infection occurs in almost
all cases and the onset of chronic hepatitis in the great
majority of these patients. The patients’ survival rate is
reduced as the disease is more aggressive after
transplantation. Effective management strategies are
therefore required. From a therapeutic point of view, the
problem may be tackled in three ways: through pre-
transplant prophylaxis (to prevent the infection of the
transplanted organ); post-transplant prophylaxis (to reduce
the possibility of developing acute hepatitis); and through a
stage to be considered once the chronic disease has already
Figure 3 Factors impacting on disease progression post-OLT.
Abbreviations: CMV, cytomegalo-virus; FCH, fibrosing cholestatic hepatitis; HCV RNA, hepatitis C virus RNA; HLA, human leucocyte antigen; OLT, orthotopic liver
transplantation.Therapeutics and Clinical Risk Management 2006:2(1) 42
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set in and stabilized. The pre-transplant stage is scarcely
applicable because of the frequent intolerance to the therapy
and the high incidence of side effects that limit its use in
these high risk patients with a serious clinical situation (Saab
and Wang 2003). However, this approach is supported by
evidence suggesting that pre-transplant interferon therapy
may delay/prevent post-transplant reinfection if associated
to a virologic response (Forns et al 2003; Thomas et al 2003),
but the matter needs to be analysed more thoroughly.
It is not yet clear whether the severity of recurrent
hepatitis is reduced after the pre-transplant therapy. Little
information is available so far on the early post-transplant
stage, and results are not clear, depending widely on when
the therapy is started and on the kind of patient (who ought
to be treated at a very early stage after transplant, at a time
that cannot be critical yet with reference to specific
complications). The studies currently available in this respect
have assessed the treatment of interferon alfa begun 2 weeks
to 1 month after the operation (Sheiner et al 1998; Singh et
al 1998; Mazzaferro et al 2001; Chalasani et al 2005).
These trials have demonstrated that an early antiviral
treatment with interferon after transplant seems to offer some
benefits in terms of reduction in hepatitis recurrences,
suggesting further elaborations. The sustained virologic
response, when assessed, has yielded very different results:
33% in the study by Mazzaferro et al (2001) and much lower
(8%) in the study by Chalasani et al (2005). The main doubts
on this approach include the appropriate time for the
beginning of therapy after transplant, as the available interval
of time for treatment is practically inexistent since the virus
can already be detected few hours after transplant. Treatment
should therefore be started at an even earlier stage. However,
starting therapy too early after transplant may cause
rejection. Most studies and attempts to treat hepatitis C
relapses after transplant have involved patients with
stabilized chronic infection. Some data in this respect
regarding interferon-alfa have not yielded the expected
results, especially in terms of sustained virologic response,
which is always very low (< 3%) ((Wright et al 1994; Feray
et al 1995; Gane et al 1998; Ahmad et al 2001; Colter et al
2001) (Figure 4).
Some progress was made through the introduction of
ribavirin in addition to interferon alfa, but most data stem
from uncontrolled studies. A study by Bizollon et al (1997)
on 21 patients who had undergone liver transplant and had
been treated with interferon alfa-2b (3 MU three times a
week) plus ribavirin 1000–1200 mg/day for 6 months,
followed by 6 months of therapy with ribavirin alone, has
shown that 100% of patients had ALT normalization at the
end of the treatment with interferon, while 48% had
undetectable HCV RNA. At the end of the follow-up, 94%
of patients still had normalized serum ALT levels, while
HCV RNA reappeared in 28% of treated patients. Other
studies have produced uneven results. Gopal et al (2001)
have reported (in a total of 12 patients) an early virologic
response in 50% of patients treated with the combined
therapy of interferon plus ribavirin, and a sustained virologic
response in 8% of cases. Another study by Alberti et al
(2001) involving 18 patients has recorded an early virologic
response in 44% of cases and sustained virologic response
in 27% of them, while in a study by Narayanan et al (2002)
involving 26 patients, percentages amounted to 35% and
23% respectively. Similar values were obtained by a study
by Lavezzo et al (2002). The only controlled study is a trial
by Samuel et al (2003) on 52 patients who had undergone
liver transplant with recurrent chronic hepatitis C
randomized to receive a combination of interferon alfa-2b
(3 MU three times a week) and ribavirin 1000–1200 mg/
day for one year, or no treatment. The trial showed that the
HCV RNA serum levels had become undetectable in 32%
of patients at the end of the treatment, and in 21.4% of cases
at the end of the follow-up period (6 months after the end
of treatment). Adverse events caused 43% of patients to
discontinue treatment.
The introduction of interferon, whose possible efficacy
in patients with a hepatitis C relapse after liver transplant
was revealed in a recent study by Chalasani et al (2005),
has opened a new scenario. The study consists of two
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Figure 4 Interferon alfa monotherapy for established recurrent hepatitis C
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controlled trials: prophylaxis and treatment. The purpose
was to assess the efficacy and safety of the treatment with
peginterferon alfa-2a in patients who had undergone liver
transplantation. The prophylaxis trial enrolled 54 patients
within 3 weeks from the transplant and the treatment trial
involved 67 patients. In this case the treatment began 6–60
months after transplantation. Patients were randomly
assigned to monotherapy with peginterferon alfa-2a 180 mcg
once a week, or to no treatment for 48 weeks and were
followed-up for 24 additional weeks. The results were not
satisfactory. In the prophylaxis trial, the sustained virologic
response amounted to 8% and was null in the nontreated
control group. In the treatment trial, the sustained virologic
response amounted to 12% of treated patients (Figure 5).
In the prophylaxis trial, 31% of treated patients and 32%
of nontreated patients discontinued therapy, whereas in the
treatment trial these percentages amounted to 30% and 19%
respectively. With regard to the combination of peginterferon
and ribavirin, the only data currently available relate to
peginterferon alfa-2b and in a limited range of patients.
Results vary; the sustained virologic response varies from
31% to 12% (Mukherjee et al 2003; Neff et al 2004;
Rodriguez-Luna et al 2004; Ross et al 2004). In one case,
high sustained virologic response rates (45%) were recorded
(Dumortier et al 2004) (Figure 6). The most recent data in
this respect derive from a study involving well defined
patient profiles presented at the last FIMAD Congress
(Genoa; 12–16 Mar 2005) by Saettone et al (2005). THIS
involved 45 naïve patients with relapsing post-transplant
HCV accompanied by high ALT values, histologic
inflammation of grade > 4/18 (Ishak score), HbA1c > 9 g/dL;
leucocytes (white blood cell count [WBC]) > 2500/mmc,
and platelets > 50 000/mmc. The therapy consisted in
peginterferon alfa-2b 1.0 mcg/kg/week plus ribavirin for
12 months. The analysis of baseline characteristics of
patients revealed that the average age was 53 years (range
32–63), 35 were male and 73% had genotype 1 or 4. Mean
HCV RNA levels amounted to1.5x10
4 UI/ml and mean ALT
values to 170 UI ± 131. The treatment began from 2 to 114
months after transplantation. The results have shown an
early virologic response in 30% of patients with genotype
1 or 4 and in 100% of cases among patients with genotype
2 or 3. The sustained virologic response was of 15% and
83% respectively. Eighty-five percent of patients asked for
the dose to be reduced and 51% discontinued therapy.
The available studies so far indicate, therefore, that today
the combination of peginterferon plus ribavirin plays a
potentially important role in patients who have undergone
a liver transplant with hepatitis C relapse, as it enables an
increase in the virologic response, which is still lower than
the one recorded in nontransplanted patients. There are still
some unresolved questions as to when the treatment ought
to be started and the exact target of patients.
Conclusions
Liver transplantation for end-stage liver disease due to HCV
infection is a world wide social and medical problem.
Epidemiological data suggest that the increase in request
for liver transplantation over the next few years will not be
supported by an adequate increase in the number of donors.
The clinical outcome of the transplanted patients in most
cases is characterised by HCV reinfection and development
of chronic hepatitis. Management of HCV in the transplant
setting is still an open issue. The therapeutic strategies being
addressed include: pre-transplant prophylaxis (to prevent
the infection of the transplanted organ); post- transplant
prophylaxis (to reduce the possibility of developing acute
hepatitis); and management once the chronic disease has
already set in and stabilized.
Combination therapy with Peginterferon alfa-2b plus
Ribavirin seems to play an important role for patients with
established recurrent hepatitis C.
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